NeurogesX News
Most Popular NeurogesX Story
NeurogesX pain patch fails a late-stage trial
NeurogesX says its dermal patch pain therapy--NGX-4010--failed a late stage study. Researchers say that patients getting the NGX-4010 patch achieved a 29.5 percent reduction in pain from baseline... Read more...
Latest Headlines
- November 17, 2009
- June 22, 2009
- February 28, 2008
- September 4, 2007
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
